Clover's booster demonstrates robust neutralization of dominant Omicron variant

Clover Biopharmaceuticals (HKEX: 02197), a Chinese vaccines and biologics company, has announced positive Phase II/III trial data demonstrating that its lead COVID-19 vaccine candidate, SCB-2019, elicited a robust immune response to the Omicron BA.5 subvariant, the dominant SARS-CoV-2 variant circulating globally today.

According to the company, this new data adds to the growing body of consistent evidence supporting the potential use of SCB-2019 as a universal COVID-19 booster vaccine to address the dominant variant and potently cross-neutralize Omicron subvariants.

"This new data makes clear the immediate potential for SCB-2019 to neutralize the Omicron BA.5 subvariant, the current major public health threat from COVID-19 globally," said Nicholas Jackson, president of global research and development at Clover. "It builds upon the full breadth of our development of SCB-2019 as a universal booster demonstrating broad neutralization against the most current Omicron lineages and all variants of concern to date."